口服塞利尼索用于晚期或复发性子宫内膜癌一线化疗后的维持治疗
ENGOT-EN5/GOG-3055/SIENDO是一项随机、前瞻性、多中心、双盲、安慰剂对照III期研究,纳入263例完成一线含铂化疗后获部分或完全缓解的晚期或复发性子宫内膜癌患者,按2:1随机接受每周一次口服塞利尼索80 mg或安慰剂。意向治疗人群的中位无进展生存期(PFS)塞利尼索组为5.7个月,安慰剂组为3.8个月(HR 0.76,95%CI 0.54-1.08;双侧P=0.126),未达统计学显著性;在审计分层数据的预设探索性分析中,PFS达到统计学显著性阈值(HR 0.71,95%CI 0.499-0.996;双侧P=0.049)。
要点
- 意向治疗人群PFS:塞利尼索组5.7个月 vs 安慰剂组3.8个月,HR 0.76,未达统计学显著。
- 审计分层数据预设探索性分析:HR 0.71(95%CI 0.499-0.996;双侧P=0.049),达到统计学显著性阈值。
- TP53野生型患者中位PFS:塞利尼索组13.7个月,安慰剂组3.7个月。
核心结论
- PFS的显著性水平仅在审计分析中达到,预设探索性亚组TP53野生型子宫内膜癌患者中塞利尼索维持治疗显示出有前景的结果。
研究设计与样本
- ENGOT-EN5/GOG-3055/SIENDO为随机、前瞻性、多中心、双盲、安慰剂对照III期研究,在10个国家107个中心开展。
- 纳入18岁及以上组织学确诊的子宫内膜癌患者,均已完成单线至少12周紫杉烷-铂类联合化疗并达到部分或完全缓解。
- 患者按2:1随机分配接受每周一次口服塞利尼索80 mg或安慰剂(ClinicalTrials.gov注册号NCT03555422)。
- 2018年1月至2021年12月期间共随机分配263例患者,其中塞利尼索组174例,安慰剂组89例。
主要发现
- 意向治疗人群中位PFS:塞利尼索组5.7个月(95%CI 3.81-9.20) vs 安慰剂组3.8个月(95%CI 3.68-7.39),HR 0.76(95%CI 0.54-1.08),双侧P=0.126,未达到统计学显著性标准。
- 发现7例(2.7%)患者化疗反应分层数据不正确。
- 审计分层数据的预设探索性PFS分析中,塞利尼索组HR 0.71(95%CI 0.499-0.996),双侧P=0.049,达到统计学显著性阈值。
- TP53野生型子宫内膜癌患者中位PFS:塞利尼索组13.7个月,安慰剂组3.7个月。
- 最常见的3级治疗相关不良事件为恶心(9%)、中性粒细胞减少(9%)和血小板减少(7%)。
关键数值与推荐
- 意向治疗人群PFS:塞利尼索组5.7个月(95%CI 3.81-9.20) vs 安慰剂组3.8个月(95%CI 3.68-7.39),HR 0.76(95%CI 0.54-1.08),双侧P=0.126。
- 审计分层数据预设探索性分析PFS:HR 0.71(95%CI 0.499-0.996),双侧P=0.049。
- TP53野生型患者中位PFS:塞利尼索组13.7个月 vs 安慰剂组3.7个月。
- 3级治疗相关不良事件:恶心9%,中性粒细胞减少9%,血小板减少7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor in patients with advanced or recurrent EC. PATIENTS AND METHODS: ENGOT-EN5/GOG-3055/SIENDO was a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites in 10 countries. Patients 18 years or older with histologically confirmed EC were enrolled. All had completed a single line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complete response. Patients were assigned to receive 80 mg oral selinexor once weekly or placebo with 2:1 random assignment (ClinicalTrials.gov identifier: NCT03555422). RESULTS: Between January 2018 and December 2021, 263 patients were randomly assigned, with 174 allocated to selinexor and 89 to placebo. The median PFS was 5.7 months (95% CI, 3.81 to 9.20) with selinexor versus 3.8 months (95% CI, 3.68 to 7.39) with placebo (hazard ratio [HR], 0.76 [95% CI, 0.54 to 1.08]; two-sided P = .126), which did not meet the criteria for statistical significance in the intent-to-treat population. Incorrect chemotherapy response stratification data for 7 (2.7%) patients were identified. In a prespecified exploratory analysis of PFS in audited stratification data, PFS for selinexor met the threshold for statistical significance (HR, 0.71; 95% CI, 0.499 to 0.996; two-sided P = .049). Furthermore, patients with the TP53 wild-type (wt) EC had a median PFS of 13.7 and 3.7 months with selinexor and placebo. The most common grade 3 treatment-related adverse events were nausea (9%), neutropenia (9%), and thrombocytopenia (7%). CONCLUSION: The significance level for PFS was only met in the audited analysis. However, a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt EC showed promising results with selinexor maintenance therapy.
引用
- Vergote I, Pérez-Fidalgo JA, Hamilton EP, et al. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023. PMID: 37669480. doi:10.1200/JCO.22.02906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。